Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics
Marine-derived compounds represent a rich source of structurally diverse molecules with therapeutic potential for cancer, renal disorders, metabolic-associated fatty liver disease (MAFLD), and atherosclerosis. This review systematically evaluates recent advances, highlighting compounds such as Micro...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Marine Drugs |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1660-3397/23/7/283 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849303533279510528 |
|---|---|
| author | Jinwei Zhang |
| author_facet | Jinwei Zhang |
| author_sort | Jinwei Zhang |
| collection | DOAJ |
| description | Marine-derived compounds represent a rich source of structurally diverse molecules with therapeutic potential for cancer, renal disorders, metabolic-associated fatty liver disease (MAFLD), and atherosclerosis. This review systematically evaluates recent advances, highlighting compounds such as Microcolin H, Benzosceptrin C, S14, HN-001, Equisetin, glycosides (e.g., cucumarioside A<sub>2</sub>-2), ilimaquinone, and Aplidin (plitidepsin). Key mechanisms include autophagy modulation, immune checkpoint inhibition, anti-inflammatory effects, and mitochondrial homeostasis. Novel findings reveal glycosides’ dual role in cytotoxicity and immunomodulation, ilimaquinone’s induction of the DNA damage response, and Aplidin’s disruption of protein synthesis via eEF1A2 binding. Pharmacokinetic challenges and structure–activity relationships are critically analyzed, emphasizing nanodelivery systems and synthetic analog development. This review bridges mechanistic insights with translational potential, offering a cohesive framework for future drug development. |
| format | Article |
| id | doaj-art-b7ce7bc8fe83439a9f9d36f3890ec129 |
| institution | Kabale University |
| issn | 1660-3397 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Marine Drugs |
| spelling | doaj-art-b7ce7bc8fe83439a9f9d36f3890ec1292025-08-20T03:58:26ZengMDPI AGMarine Drugs1660-33972025-07-0123728310.3390/md23070283Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease TherapeuticsJinwei Zhang0Institute of Biomedical and Clinical Sciences, Medical School, Faculty of Health and Life Sciences, Hatherly Laboratories, Streatham Campus, University of Exeter, Exeter EX4 4PS, UKMarine-derived compounds represent a rich source of structurally diverse molecules with therapeutic potential for cancer, renal disorders, metabolic-associated fatty liver disease (MAFLD), and atherosclerosis. This review systematically evaluates recent advances, highlighting compounds such as Microcolin H, Benzosceptrin C, S14, HN-001, Equisetin, glycosides (e.g., cucumarioside A<sub>2</sub>-2), ilimaquinone, and Aplidin (plitidepsin). Key mechanisms include autophagy modulation, immune checkpoint inhibition, anti-inflammatory effects, and mitochondrial homeostasis. Novel findings reveal glycosides’ dual role in cytotoxicity and immunomodulation, ilimaquinone’s induction of the DNA damage response, and Aplidin’s disruption of protein synthesis via eEF1A2 binding. Pharmacokinetic challenges and structure–activity relationships are critically analyzed, emphasizing nanodelivery systems and synthetic analog development. This review bridges mechanistic insights with translational potential, offering a cohesive framework for future drug development.https://www.mdpi.com/1660-3397/23/7/283marine-derived compoundscancer therapyrenal diseaseautophagymetabolic-associated fatty liver diseaseimmune checkpoint inhibitors |
| spellingShingle | Jinwei Zhang Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics Marine Drugs marine-derived compounds cancer therapy renal disease autophagy metabolic-associated fatty liver disease immune checkpoint inhibitors |
| title | Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics |
| title_full | Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics |
| title_fullStr | Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics |
| title_full_unstemmed | Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics |
| title_short | Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics |
| title_sort | marine derived compounds a new horizon in cancer renal and metabolic disease therapeutics |
| topic | marine-derived compounds cancer therapy renal disease autophagy metabolic-associated fatty liver disease immune checkpoint inhibitors |
| url | https://www.mdpi.com/1660-3397/23/7/283 |
| work_keys_str_mv | AT jinweizhang marinederivedcompoundsanewhorizonincancerrenalandmetabolicdiseasetherapeutics |